Summary

Market Size & Trends

The Middle East plasmid DNA manufacturing market size was estimated at USD 45.3 million in 2024 and is expected to reach USD 186.5 million by 2033, expanding at a CAGR of 17.43% from 2025 to 2033. Growth is driven by increasing investments in biotechnology, the expansion of GMP-compliant facilities, and supportive government initiatives under national life sciences strategies. Strategic partnerships with global biopharma companies, coupled with advanced R&D infrastructure and strong logistics capabilities, are further enhancing the region’s position as a competitive hub for plasmid DNA production.

Increased Investment in Healthcare Transformation

Under Vision 2030, Saudi Arabia is committing over USD 65 billion to transform its healthcare system. The initiative aims to revamp infrastructure, establish 21 health clusters, scale up e-health services, and increase private sector participation from 40% to 65% by 2030. The Kingdom is also accelerating efforts to localize pharmaceutical production, reduce import dependence, and boost value creation in life sciences. These reforms are designed to enhance quality, accessibility, and efficiency while opening the market to global partnerships.

India, with its globally competitive pharmaceutical industry, is well-positioned to support Saudi Arabia’s diversification in healthcare. Accounting for about 20% of global generic medicine exports and being the world’s largest vaccine producer by volume, India offers affordable, high-quality healthcare solutions. Its strong track record in global vaccine supply and pharmaceutical manufacturing demonstrates reliability and the capacity to meet large-scale demand. During the COVID-19 pandemic, India supplied millions of vaccine doses to Saudi Arabia, reinforcing its role as a strategic healthcare partner.

To fully capitalize on this synergy, streamlined regulatory cooperation, technology transfer agreements, and localization incentives will be critical. Saudi procurement authorities are encouraging domestic manufacturing through offtake agreements and strategic partnerships. Several Indian pharmaceutical firms have already entered the Saudi market, secured local regulatory approvals and established a presence. Joint ventures and localized production facilities are expected to further strengthen bilateral trade, enhance Saudi self-sufficiency in essential medicines, and provide a gateway for Indian companies to access the broader MENA healthcare market.

Middle East Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East plasmid DNA manufacturing market report on the basis of grade, development phase, application, disease, and country:

• Grade Outlook (Revenue, USD Million, 2021 - 2033)
• R&D Grade
o Viral Vector Development
o AAV
o Lentivirus
o Adenovirus
o Retrovirus
o Others
o mRNA Development
o Antibody Development
o DNA Vaccine Development
o Others
• GMP Grade
• Development Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Clinical Therapeutics
• Clinical Therapeutics
• Marketed Therapeutics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Vaccines
• Cell & Gene Therapy
• Immunotherapy
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Disease
• Cancer
• Genetic Disorder
• Others
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Saudi Arabia
• UAE
• Kuwait
• Qatar
• Oman
• Rest of Middle East

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Grade
1.2.2. Development Phase
1.2.3. Application
1.2.4. Disease
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Middle East Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising demand for advanced therapies
3.2.1.2. Expansion of clinical research activities
3.2.2. Market restraint analysis
3.2.2.1. Limited regional manufacturing infrastructure
3.2.2.2. High production cost
3.3. Middle East Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Middle East Plasmid DNA Manufacturing Market: Grade Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Plasmid DNA Manufacturing Market Grade Movement Analysis
4.3. Middle East Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
4.4. R&D Grade
4.4.1. R&D grade market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Viral Vector Development
4.4.2.1. Viral vector development market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.2. AAV
4.4.2.2.1. AAV market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.3. Lentivirus
4.4.2.3.1. Lentivirus market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.4. Adenovirus
4.4.2.4.1. Adenovirus market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.5. Retrovirus
4.4.2.5.1. Retrovirus market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2.6. Others
4.4.2.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. mRNA Development
4.4.3.1. mRNA development market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Antibody Development
4.4.4.1. Antibody development market estimates and forecasts 2021 to 2033 (USD Million)
4.4.5. DNA Vaccine Development
4.4.5.1. DNA vaccine development market estimates and forecasts 2021 to 2033 (USD Million)
4.4.6. Others
4.4.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.5. GMP Grade
4.5.1. GMP grade market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Middle East Plasmid DNA Manufacturing Market: Development Phase Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Plasmid DNA Manufacturing Market Development Phase Movement Analysis
5.3. Middle East Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
5.4. Pre-clinical Therapeutics
5.4.1. Pre-clinical therapeutics market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Clinical Therapeutics
5.5.1. Clinical therapeutics market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Marketed Therapeutics
5.6.1. Marketed therapeutics market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Middle East Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Plasmid DNA Manufacturing Market Application Movement Analysis
6.3. Middle East Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. DNA Vaccines
6.4.1. DNA vaccines market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Cell & Gene Therapy
6.5.1. Cell & gene therapy market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Immunotherapy
6.6.1. Immunotherapy market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Middle East Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Plasmid DNA Manufacturing Market Disease Movement Analysis
7.3. Middle East Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
7.4. Infectious Disease
7.4.1. Infectious disease market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Cancer
7.5.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Genetic Disorder
7.6.1. Genetic disorder market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Others
7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Middle East Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
8.1. Country Market Share Analysis, 2024 & 2033
8.2. Country Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. Middle East
8.4.1. Saudi Arabia
8.4.1.1. Key country dynamics
8.4.1.2. Competitive scenario
8.4.1.3. Regulatory landscape
8.4.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. UAE
8.4.2.1. Key country dynamics
8.4.2.2. Competitive scenario
8.4.2.3. Regulatory landscape
8.4.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Kuwait
8.4.3.1. Key country dynamics
8.4.3.2. Competitive scenario
8.4.3.3. Regulatory landscape
8.4.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Qatar
8.4.4.1. Key country dynamics
8.4.4.2. Competitive scenario
8.4.4.3. Regulatory landscape
8.4.4.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
8.4.5. Oman
8.4.5.1. Key country dynamics
8.4.5.2. Competitive scenario
8.4.5.3. Regulatory landscape
8.4.5.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
8.4.6. Rest of Middle East
8.4.6.1. Key country dynamics
8.4.6.2. Competitive scenario
8.4.6.3. Regulatory landscape
8.4.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Charles River Laboratories
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Service benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Danaher
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Service benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Lonza Group
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Service benchmarking
9.4.3.4. Strategic initiatives
9.4.4. VGXI, Inc.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Service benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Kaneka Corp.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Service benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Eurofins Genomics
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Service benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Luminous BioSciences, LLC
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Service benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Cell & Gene Therapy Catapult
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Service benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Nature Technology
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Service benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Akron Biotech
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Service benchmarking
9.4.10.4. Strategic initiatives